AXLA Stock Overview
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Axcella Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$41.25 |
| 52 Week Low | US$0.34 |
| Beta | 0.58 |
| 11 Month Change | -59.87% |
| 3 Month Change | -96.16% |
| 1 Year Change | -95.10% |
| 33 Year Change | -99.69% |
| 5 Year Change | n/a |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Axcella Therapeutics drops 9% on $34.2M stock offering
Oct 13Axcella adds 20% as mid-stage trial indicates potential of NASH therapy
Sep 29Axcella Health GAAP EPS of -$0.40 misses by $0.02
Aug 12Axcella Health: Revisiting A Lottery Ticket
Apr 25Axcella Health EPS beats by $0.01
May 06Have Insiders Been Buying Axcella Health Inc. (NASDAQ:AXLA) Shares This Year?
Feb 19
Axcella decides not to expand enrollment in AXA4010-001 following cohort 1 readout
Jan 11Is Axcella Health Inc.'s (NASDAQ:AXLA) Shareholder Ownership Skewed Towards Insiders?
Dec 28
Shareholder Returns
| AXLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.8% | 2.5% | 1.0% |
| 1Y | -95.1% | 15.6% | 31.4% |
Return vs Industry: AXLA underperformed the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: AXLA underperformed the US Market which returned 24.3% over the past year.
Price Volatility
| AXLA volatility | |
|---|---|
| AXLA Average Weekly Movement | 21.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AXLA's share price has been volatile over the past 3 months.
Volatility Over Time: AXLA's weekly volatility has decreased from 51% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 11 | Craig Jalbert | www.axcellahealth.com |
Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence.
Axcella Health Inc. Fundamentals Summary
| AXLA fundamental statistics | |
|---|---|
| Market cap | US$1.30m |
| Earnings (TTM) | -US$48.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs AXLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$48.23m |
| Earnings | -US$48.23m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.36 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AXLA perform over the long term?
See historical performance and comparison